Trial · NCT02652806
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hb mean change from baseline | Weeks 23 to 27. | Hb mean change from baseline |
| Secondary | Mean change from baseline in low-density lipoprotein (LDL) cholesterol | Weeks 25-27 | Mean change from baseline in low-density lipoprotein (LDL) cholesterol |
| Secondary | Number of subjects with a Hb response | Weeks 23-27 | Number of subjects with a Hb response (as defined per protocol) |
| Secondary | Percent of subjects with a Hb response | Weeks 23-27 | Percent of subjects with a Hb response (as defined per protocol) |
| Secondary | Effect on iron metabolism | Week 27 | Measurement of serum iron |
| Secondary | Proportion of subjects with exacerbation of hypertension | Up to Week 27 | Proportion of subjects with exacerbation of hypertension, meeting at least one of the following criteria up to Week 27: * Increase in anti-hypertensive medication use, * Adverse event of hypertension, or * Increases from baseline in blood pressure confirmed by repeat measurement at next visit unless anti-hypertensive medications are changed. |
| Secondary | Mean change from baseline in predialysis and postdialysis mean arterial blood pressure | Weeks 23-27 | Mean arterial blood pressure measured pre-and post-dialysis. |
| Secondary | Number of subjects with treatment-emergent adverse events (TEAEs). | Week 1 to up to Week 53 | Number of subjects with treatment-emergent adverse events (TEAEs). |
| Secondary | Percent of subjects with treatment-emergent adverse events (TEAEs). | Week 1 to up to Week 53 | Percent of subjects with treatment-emergent adverse events (TEAEs). |
| Secondary | Changes from baseline in vital signs | Week 1 to up to Week 53 | Measurement of vital signs |
| Secondary | Changes from baseline in ECG findings. | Week 1 to up to Week 53 | ECG recordings. |
| Secondary | Changes from baseline in clinical laboratory values. | Week 1 to up to Week 53 | Clinical laboratory values. |
| Secondary | Number and % of subjects on rescue therapy during study treatment. | Week 1 to up to Week 53 | Number and % of subjects on rescue therapy during study treatment. |
| Secondary | Time to rescue therapy from date of first dose during study treatment. | Week 1 to up to Week 53 | Time to rescue therapy from date of first dose during study treatment. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02652806/registered